Literature DB >> 11175316

Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope.

A Gambotto1, G Dworacki, V Cicinnati, T Kenniston, J Steitz, T Tüting, P D Robbins, A B DeLeo.   

Abstract

Enhanced green fluorescent protein (EGFP) is a novel marker gene product, which is readily detectable using techniques of fluorescence microscopy, flow cytometry, or macroscopic imaging. In the present studies, we have examined the immunogenicity of EGFP in murine models. A stable transfectant of the transplantable CMS4 sarcoma of BALB/c origin expressing EGFP, CMS4-EGFP-Zeo, was generated. Splenocytes harvested from mice immunized with a recombinant adenovirus expressing EGFP (Ad-EGFP) were restimulated in vitro with CMS4-EGFP-Zeo. Effector lymphocytes displayed strong cytotoxicity against CMS4-EGFP-Zeo, but not against mock-transfected CMS4-Zeo tumor cells. A number of candidate H2-Kd-binding peptides derived from the EGFP protein were chosen according to an epitope prediction program and synthesized. These peptides were tested for their ability to bind to H2-Kd molecules and stimulate IFNgamma-production by splenocytes harvested from Ad-EGFP-immunized mice. Using this methodology, the peptide, HYLSTQSAL (corresponding to EGFP200-208) which strongly binds to H2-Kd molecules, was identified as a naturally occurring epitope of EGFP. These results should facilitate the use of EGFP as a model tumor antigen in BALB/c mice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11175316     DOI: 10.1038/sj.gt.3301335

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  55 in total

1.  IKKβ-induced inflammation impacts the kinetics but not the magnitude of the immune response to a viral vector.

Authors:  Emily L Hopewell; Crystina C Bronk; Michael Massengill; Robert W Engelman; Amer A Beg
Journal:  Eur J Immunol       Date:  2012-01-13       Impact factor: 5.532

2.  Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses.

Authors:  Camilo Cuadros; Francisco J Lopez-Hernandez; Ana Lucia Dominguez; Michael McClelland; Joseph Lustgarten
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

3.  New lines of GFP transgenic rats relevant for regenerative medicine and gene therapy.

Authors:  S Remy; L Tesson; C Usal; S Menoret; V Bonnamain; V Nerriere-Daguin; J Rossignol; C Boyer; T H Nguyen; P Naveilhan; L Lescaudron; I Anegon
Journal:  Transgenic Res       Date:  2010-01-22       Impact factor: 2.788

4.  Widespread gene transfer to malignant gliomas with In vitro-to-In vivo correlation.

Authors:  Karina Negron; Namir Khalasawi; Billy Lu; Chi-Ying Ho; Jason Lee; Siddharth Shenoy; Hai-Quan Mao; Tza-Huei Wang; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2019-04-09       Impact factor: 9.776

5.  Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response.

Authors:  Piotr Hadaczek; John Forsayeth; Hanna Mirek; Keith Munson; John Bringas; Phil Pivirotto; Jodi L McBride; Beverly L Davidson; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2009-03       Impact factor: 5.695

6.  Effects of Culturing on the Stability of the Putative Murine Adipose Derived Stem Cells Markers.

Authors:  Jacquelyn R Maddox; Xinbo Liao; Feng Li; Christopher Niyibizi
Journal:  Open Stem Cell J       Date:  2009-01-01

7.  Transient immunosuppression stops rejection of virus-transduced enhanced green fluorescent protein in rabbit retina.

Authors:  Kentaro Doi; Jian Kong; Janos Hargitai; Stephen P Goff; Peter Gouras
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

8.  Transgene expression levels determine the immunogenicity of transduced hematopoietic grafts in partially myeloablated mice.

Authors:  Herena Eixarch; Alba Gómez; Elisabeth Kádár; Mónica George; Nuria Martínez; Carmen Espejo; Jordi Pétriz; Ramon Gimeno; Jordi Barquinero
Journal:  Mol Ther       Date:  2009-08-25       Impact factor: 11.454

9.  Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria.

Authors:  Simon J Draper; Anna L Goodman; Sumi Biswas; Emily K Forbes; Anne C Moore; Sarah C Gilbert; Adrian V S Hill
Journal:  Cell Host Microbe       Date:  2009-01-22       Impact factor: 21.023

10.  Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Camila Santucci; Brian Tran; Robert Langer; Gregory T Zugates; Daniel G Anderson; Richard S Kornbluth
Journal:  PLoS One       Date:  2009-10-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.